The researchers found that Maharashtra reported the highest number of samples, 91, consisting of the N440K mutant of the 772 Covid virus genes sequenced. Telangana reported 81 samples with the variant in the 773 samples sequenced. Karnataka reported 54 in the 339 samples sequenced.
“We will have a good amount of data on children in this age group. If everything goes well in terms of safety, the vaccine will potentially be approved for use in children aged 12 to 18 years,” said Dr Sharvil Patel, managing director, Cadila Healthcare Limited
AHMEDABAD: After covering adults and children aged between12 and18 years under the ongoing clinical trials of its Covid-19 vaccine ZyKov-D, Zydus Cadila now plans to test its plasmid DNA vaccine for children in the age group of 5 to 12 years.
The pharma major has already covered 800-plus children in 12-18 years clinical trials. “We will have a good amount of data on children in this age group. If everything goes well in terms of safety, the vaccine will potentially be approved for use in children aged 12 to 18 years,” said Dr Sharvil Patel, managing director, Cadila Healthcare Limited, the flagship company of the Ahmedabad-based Zydus Cadila Group.